UK / Fastest Growing Private Pharmacos; GSK Shake-Up; Brexit Uncertainties; COVID-19 Reinfection Trial
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
Brexit
Europe / Vaccine Wars: What the EU/AstraZeneca Row Shows Us About Pharma Cross-Border Litigation
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
In Conversation
Geoffrey Guy, Chairman, GW Pharma
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will create for Britain and the life sciences industry in the…
Brexit Facts & Figures Snapshot
There is much debate surrounding the potential impact on the UK’s life sciences industry of the…
Related Report
Turkey / The Impact Of Brexit On CE Certificates Issued By UK Notified Bodies
The shockwaves from the UK’s exit from the European Union have resounded across the continent, including in…
Europe: Political Complexity Bodes Poorly for Pharma
Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe –…
Brexit uncertainty forces AstraZeneca to freeze investment in the UK
Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on…
Europe / After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the…
The European Medicines Verification System Launches to Tackle Fake Drugs
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use…
Brexit: A Window of Opportunity for France’s Drug Regulator?
As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences…
Brexit Bites: EMA cuts off Britain
The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been…
Brexit: A Serious Threat to Patients
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Biotech Funding / 2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
Brexit: Much Ado About Nothing?
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect.…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
NHS England’s Long-Term Plan to be Funded by £20.5 Billion
Today NHS England have released their long-term plan to ensure the future of the NHS and the continued care of UK…
Roche boss: Brexit will make the UK less competitive
Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process.…